DeepSeek’s AI breakthrough in China has sparked a resurgence in venture capital interest, with Insilico Medicine securing a $110 million series E financing round led by Value Partners. The company, backed by Qiming Ventures, utilizes AI technology for drug development, with several drugs already approved for clinical testing. The success of DeepSeek has also attracted global investors looking to invest in Chinese AI companies, signaling a potential revival in funding opportunities.
Full Article
Loading PerspectiveSplit analysis...
